Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Temporary suspension of 15-minute observation period after vaccination to accelerate booster program

The 15 minute observation period following a vaccination with Pfizer or Moderna will be temporarily suspended as part of new measures to speed up the booster rollout as part of our emergency response to the rapid spread of the Omicron variant.

14 Dec 2021

Can you take the COVID-19 and Influenza vaccines on the same day?

Scientists have conducted a substudy within a phase 3 UK trial and have reported the safety, immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine when co-administered with licensed seasonal influenza vaccines.

19 Nov 2021

Three doses of COVID-19 mRNA vaccination safe in high-risk populations

A new study determines the safety of an additional vaccine among individuals who previously received two doses of mRNA-based COVID-19 vaccines.

15 Nov 2021

Maternal pre-pregnancy BMI linked to pediatric allergic disease development

A University of Ottawa-led study of nearly 250,000 children in Ontario over seven years – the largest of its kind – found a mother's weight before pregnancy may impact their newborn's risk of developing allergic diseases in early childhood, whereas weight gain during pregnancy did not seem to have the same effect.

1 Nov 2021

Medical staff with a history of allergy suffered adverse reactions to BNT162b2 COVID-19 vaccine

Scientists have addressed the gap in the research regarding the adverse reactions to the COVID-19 vaccine among individuals with allergies.

20 Sep 2021

COVID-19 vaccine-related allergies are rare, typically mild and treatable, finds study

Allergic reactions to the new mRNA-based COVID-19 vaccines are rare, typically mild and treatable, and they should not deter people from becoming vaccinated, according to research from the Stanford University School of Medicine.

20 Sep 2021

Researchers find no serious health effects linked to mRNA COVID-19 vaccines

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.

4 Sep 2021

FDA approves an intravenous medication to treat patients with Pompe disease

Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.

6 Aug 2021

Study reports on COVID-19 vaccine-related adverse events in young Japanese population

A new study from Japan, released as a medRxiv* preprint, describes the adverse effects associated with the vaccine. Such data is crucial in delineating the safety and efficacy of this intervention in various age groups.

6 Aug 2021

Phase 1/2 trial results for Nanocovax, protein subunit SARS-CoV-2 vaccine from Vietnam

Nanocovax is a protein subunit vaccine that contains the full-length spike stabilized by the addition of two prolines

29 Jul 2021

Study reveals safety of second mRNA COVID-19 vaccine dose after allergic reactions to first dose

In a multi-hospital analysis of individuals who experienced an allergic reaction to their first mRNA COVID-19 vaccine dose, all patients who went on to receive a second dose tolerated it without complications.

26 Jul 2021

mRNA COVID-19 vaccines may increase patients' concerns about side effects

Vivid photos of the red "COVID arm" rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy.

23 Jun 2021

Updated ACR position statement on patient safety and site of service for biologics released

The American College of Rheumatology has released an updated position statement on patient safety and site of service for biologics outlining several reasons why the ACR strongly believes infusions should be administered in a monitored health care setting with onsite supervision by a provider with appropriate training in biologic infusions.

21 Jun 2021

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.

13 Jun 2021

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

New research from a team of scientists at the Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University in Canada, has aimed to determine the potential causes of anaphylaxis or allergic reactions reported in some individuals after receiving COVID-19 vaccines, including the mRNA vaccines by Pfizer-BioNTech and Moderna.

1 Jun 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

People with venom allergies are more likely to have bone marrow disorder

Researchers at Michigan Medicine found that people with venom allergies are much more likely to suffer mastocytosis, a bone marrow disorder that causes higher risk of fatal reactions.

19 May 2021

FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 Vaccine

Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age.

10 May 2021

Changes to infant gut bacteria and food allergies are linked to C-section birth, ethnicity

Researchers have found a causal link between caesarean section birth, low intestinal microbiota and peanut sensitivity in infants, and they report the effect is more pronounced in children of Asian descent than others, in a recently published paper in the journal of the American Gastroenterological Association.

21 Apr 2021

Michigan Medicine to kick off first national study on allergic reactions to COVID-19 vaccines

In a carefully controlled study, Michigan Medicine researchers will kick off the first national trial to study allergic reactions to the COVID-19 mRNA vaccines.

7 Apr 2021